Aegerion Pharmaceuticals

IPO / Investor Relations

• Aegerion Pharmaceuticals, a late-stage clinical orphan drug company, raising capital through an initial public offering in a challenging market; needed to establish IR and corporate communications best practices and build institutional shareholder base
• Objectives of the program:
  • Facilitate a successful IPO
  • Build valuation
  • Establish corporate branding

LG Solution for Investor Relations and Corporate Strategy

• Developed qualified institutional investor target list
• Provided strategic counsel on corporate story and participated in team meetings for optimal positioning
• Managed communications during IPO road show , including NASDAQ Opening Bell ceremony on 1st day of trading
• Established follow up program with institutions that have met with management to gain insights and perceptions and turn this information into actionable counsel
• Attended investor meetings; provided ongoing recommendations and next steps for communicating with the appropriate institutional investors
• Developed new corporate presentation, fact sheet, corporate and investor relations website, corporate logo and additional elements
• Created media plan and secured financial media opportunities surrounding the IPO
• Developed messaging for quarterly earnings news release and conference call script; developed documents and handled all logistics
• Developed 2011 IR plan and strategy for implementation

Return on Investment

• $48.8M net proceeds: a successful offering in a time when many companies are postponing IPOs due to market conditions
• Priced at $9.50 on October 22, 2010; closing price as of December 30, 2010 was $14.44 – a 52% increase
• Market cap (as of 12/30/10): $254.2 million
• Brand established and being carried through all corporate materials

Integrated Communications

"2009 Bell Ringer" Merit Award for Corporate Branding

• EyeGate relocated from Paris to the US and had broad corporate communications/branding needs
• Objectives of the program:
  • Communicate the value of the company’s iontophoresis ocular delivery platform
  • Increase visibility amongst key opinion leaders, potential partners and strategic investors
  • Build their value proposition to potential investors and partners interested in ocular delivery platforms

LG Solution

• Developed an integrated communications program with key message development through LG Immersion ™ which were carried through PR, media and venture relations strategies
• Executed on corporate brand positioning through website, fact sheet, corporate advertising and corporate presentation

Return on Investment

• Investment Community: Secured US lead of a $15M Series C financing round at increased valuation from new investor Medicis Capital in a down market
• Partnerships: EyeGate is currently underway with a research and collaboration agreement with a top pharmaceutical company in antibody area; key partnership with biotech company for ocular delivery for SiRNA therapeutics
• Numerous media and analyst coverage, including Frost & Sullivan’s Technology Innovation of the Year award in Ophthalmology

Corporate Brand Building

• Company formed in 2005 and gradually acquired several well-known brands throughout the Asia-Pacific region
• Operating in 13 markets, local subsidiaries lacked a cohesive vision
• Needed to develop the Invida brand name locally in addition to raising the company’s profile throughout the U.S. and Europe to affect new partnerships and customer awareness

• Conducted LG Immersion™ , working with management committee to unify corporate vision and brand
• Overhauled company website, created imagery and content to reflect single brand identity
• Created new corporate materials, including updated Fact Sheet, corporate and investor presentations, and branding guideline book
• Executed second year PR program to build on foundation, establishing Invida as the “Gateway to Asia Pacific” region and deployment of multiple stakeholder programs

• Raised corporate profile among media, securing coverage in publications throughout the U.S., Europe, and Asia-Pacific, including Scrip, Dow Jones, mergermarket, PharmaWire, PharmAsia, and BioCentury
• Leveraged conference participation to raise company’s profile among investors and potential partners, resulting in development of key contacts and alliances
• Increased awareness with US/European partner companies as evidenced by increased deal flow and executed deals
• Unified brand identity across 13 regions in Asia and internal colleagues, increasing engagement level

Integrated Communications

Commercialization Program

• Pfizer entered into a in-licensing agreement with Protalix Biotherapeutics for the company's taliglucerase (Gaucher's Disease) product based on a plant-cell based technology
• Global commercialization need for an alternative therapy to treat Gaucher's Disease given the competitive supply issues (contamination)
• LG was tasked with developing an integrated, global pre-and post-launch commercialization and communications program that is compliant and creative for the situation

• Development of a highly specialized and unique communications program focused on differentiated product and patient access
• Insertion of agency leader on commercial team for optimal cross-functional and partnership collaboration
• Ability to adjust to partner needs as timeline and key regulatory milestones evolved

• Carefully executed communications roll-out of pre-commercial launch plan
• Strategic counsel surrounding issues management, corporate reputation and competitive intelligence
• Highly functioning account team; extension of internal business unit communications
• High-profile media placements in national outlets including the New York Times, Wall Street Journal, Boston Globe, Washington Post, Forbes and BusinessWeek
• Elevation of Pfizer's strategic initiative among internal stakeholders, analysts, advocacy groups, patients and competitors
• Development of relationships with key stakeholders, leading up to FDA approval of taliglucerase
• Internal communications management, including strategic counsel, issues management counsel, collateral development and production materials

Corporate Visibility

Award-winning Partnering Event

• Sanofi-aventis’ Cambridge location was not widely known in New England, a strategic region for the company with a cluster of innovative biopharmaceutical companies, academic universities and teaching hospitals
• Desire by management to build company profile in Cambridge to increase awareness through event and media relations

• Strategic counsel and recommendations in Plan format outlining objectives, expectations, venue, topics, target attendees and branding themes
• Creation of unique brand identity for the event including unique graphic identity and tag line
• Development and design of “Save the Date” campaign, including website pages to track responses
• Event management including development of handout materials, audio and visual support, speaker coordination, media outreach, vendor relations, and facility review
• Secured local articles in Boston Business Journal to create buzz before event; arranged facility tour with The Boston Globe

• Attendance by over 200+ guests, including local biotechnology and pharmaceuticals leaders and potential business partners
• Media attendance and coverage from Boston Globe, Dow Jones, Reuters, Xconomy and Bloomberg
• Press conference with CEO Chris Viehbacher documented by Boston Globe on-site photographer; story and photo picked up by several news outlets
• Increased awareness and understanding of sanofi-aventis and its partnership opportunities with key stakeholders as evidenced by survey results
• Awarded 2009 “Best Business Development Communications Program” Award

Investor Relations

• Late-stage clinical biotechnology company transitioning from a story stock to a revenue/earnings based model
• Mid-cap stage with eye to become large-cap status; build visibility for pipeline of products

• Conduct regular, continued perception audits with key target institutional holders to understand investor perceptions and opinions; feeding into IR strategy
• Expand overall IR program to promote growth strategy and incorporate best practice tactics used by larger cap companies
• Use agency relationships to identity opportunities for IR solutions and best practice
• Create opportunities for visibility for pipeline

• Deliver key Insights to create solid, long-term IR
• Provide best practice IR for better understanding of market dynamics affecting large pharmaceutical companies
• Deliver key Intelligence for broader investor targeting strategies
• Increase valuation over eight year period from ~$500m – $10B market cap